The Catalan blood products company has received a $21 million grant from the Michael J. Fox Foundation (MJFF) for Parkinson's ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

European equities traded in the US as American depositary receipts were climbing sharply higher late Wednesday morning, rising 1.37% to 1,315.69 on the S&P Europe Select ADR Index. From continental ...

The Michael J. Fox Foundation for Parkinson’s Research has partnered with Grifols, a global healthcare company, to identify ...

Will fund a pilot study to analyze longitudinal plasma samples covering a period of up to 10 years.

Grifols has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based ...

Spanish drugmaker Grifols has been awarded a $21 million grant from the Michael J Fox Foundation to support a pilot study to ...

The term therapeutic protein was first used to describe medicines that are genetically engineered versions of naturally occurring human proteins. Therapeutic proteins can be used to replace a protein ...

In the realm of healthcare innovation, therapeutic proteins emerge as catalysts for transformative advancements. According to the latest edition of the Global Therapeutic Protein ...

U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding ...

Mason Capital Management LLC’s Kenneth M Garschina has called the Spanish regulator’s attention to Grifols SA’s “severe lack of disclosure” as he tries to push for a board reshuffle.

Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.5% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ: GRFS) class A ...